Pharmacovigilance in pharmaceutical companies: An overview

por Mammì, Maria, Citraro, Rita, Torcasio, Giovanni, Cusato, Gennaro, Palleria, Caterina, di Paola, Eugenio Donato
Publicado 2013

Nexavar(®)-related adverse reactions: Calabrian (Italy) experience for sorafenib exposition in 2012

por Cilurzo, Felisa, Staltari, Orietta, Patanè, Marinella, Ammendola, Michele, Garaffo, Caterina, Di Paola, Eugenio Donato
Publicado 2013

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-...

por Tassone, Pierfrancesco, Di Martino, Maria Teresa, Arbitrio, Mariamena, Fiorillo, Lucia, Staropoli, Nicoletta, Ciliberto, Domenico, Cordua, Alessia, Scionti, Francesca, Bertucci, Bernardo, Salvino, Angela, Lopreiato, Mariangela, Thunarf, Fredrik, Cuomo, Onofrio, Zito, Maria Cristina, De Fina, Maria Rosanna, Brescia, Amelia, Gualtieri, Simona, Riillo, Caterina, Manti, Francesco, Caracciolo, Daniele, Barbieri, Vito, Di Paola, Eugenio Donato, Di Francesco, Adele Emanuela, Tagliaferri, Pierosandro
Publicado 2023